Literature DB >> 24467845

Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling.

Hisham Qosa1, Bilal S Abuasal1, Ignacio A Romero2, Babette Weksler3, Pierre-Oliver Couraud4, Jeffrey N Keller5, Amal Kaddoumi6.   

Abstract

Alzheimer's disease (AD) has a characteristic hallmark of amyloid-β (Aβ) accumulation in the brain. This accumulation of Aβ has been related to its faulty cerebral clearance. Indeed, preclinical studies that used mice to investigate Aβ clearance showed that efflux across blood-brain barrier (BBB) and brain degradation mediate efficient Aβ clearance. However, the contribution of each process to Aβ clearance remains unclear. Moreover, it is still uncertain how species differences between mouse and human could affect Aβ clearance. Here, a modified form of the brain efflux index method was used to estimate the contribution of BBB and brain degradation to Aβ clearance from the brain of wild type mice. We estimated that 62% of intracerebrally injected (125)I-Aβ40 is cleared across BBB while 38% is cleared by brain degradation. Furthermore, in vitro and in silico studies were performed to compare Aβ clearance between mouse and human BBB models. Kinetic studies for Aβ40 disposition in bEnd3 and hCMEC/D3 cells, representative in vitro mouse and human BBB models, respectively, demonstrated 30-fold higher rate of (125)I-Aβ40 uptake and 15-fold higher rate of degradation by bEnd3 compared to hCMEC/D3 cells. Expression studies showed both cells to express different levels of P-glycoprotein and RAGE, while LRP1 levels were comparable. Finally, we established a mechanistic model, which could successfully predict cellular levels of (125)I-Aβ40 and the rate of each process. Established mechanistic model suggested significantly higher rates of Aβ uptake and degradation in bEnd3 cells as rationale for the observed differences in (125)I-Aβ40 disposition between mouse and human BBB models. In conclusion, current study demonstrates the important role of BBB in the clearance of Aβ from the brain. Moreover, it provides insight into the differences between mouse and human BBB with regards to Aβ clearance and offer, for the first time, a mathematical model that describes Aβ clearance across BBB.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amyloid-β; Blood–brain barrier; Clearance; Mechanistic model

Mesh:

Substances:

Year:  2014        PMID: 24467845      PMCID: PMC3965363          DOI: 10.1016/j.neuropharm.2014.01.023

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  45 in total

Review 1.  Alzheimer's disease and the amyloid cascade hypothesis: ten years on.

Authors:  Bernd Sommer
Journal:  Curr Opin Pharmacol       Date:  2002-02       Impact factor: 5.547

Review 2.  Transcytosis: crossing cellular barriers.

Authors:  Pamela L Tuma; Ann L Hubbard
Journal:  Physiol Rev       Date:  2003-07       Impact factor: 37.312

3.  Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model.

Authors:  Agnès Poirier; Thierry Lavé; Renée Portmann; Marie-Elise Brun; Frank Senner; Manfred Kansy; Hans-Peter Grimm; Christoph Funk
Journal:  Drug Metab Dispos       Date:  2008-09-22       Impact factor: 3.922

4.  The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae.

Authors:  Camilla A Hansson Petersen; Nyosha Alikhani; Homira Behbahani; Birgitta Wiehager; Pavel F Pavlov; Irina Alafuzoff; Ville Leinonen; Akira Ito; Bengt Winblad; Elzbieta Glaser; Maria Ankarcrona
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

Review 5.  Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease.

Authors:  Rashid Deane; Berislav V Zlokovic
Journal:  Curr Alzheimer Res       Date:  2007-04       Impact factor: 3.498

6.  LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms.

Authors:  Rashid Deane; Zhenhua Wu; Abhay Sagare; Judianne Davis; Shi Du Yan; Katie Hamm; Feng Xu; Margaret Parisi; Barbra LaRue; Hong Wei Hu; Patricia Spijkers; Huang Guo; Xiaomei Song; Peter J Lenting; William E Van Nostrand; Berislav V Zlokovic
Journal:  Neuron       Date:  2004-08-05       Impact factor: 17.173

Review 7.  Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.

Authors:  R Deane; R D Bell; A Sagare; B V Zlokovic
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-03       Impact factor: 4.388

8.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

Authors:  T Kawarabayashi; L H Younkin; T C Saido; M Shoji; K H Ashe; S G Younkin
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

9.  Efflux of human and mouse amyloid beta proteins 1-40 and 1-42 from brain: impairment in a mouse model of Alzheimer's disease.

Authors:  W A Banks; S M Robinson; S Verma; J E Morley
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

10.  In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life.

Authors:  John R Cirrito; Patrick C May; Mark A O'Dell; Jennie W Taylor; Maia Parsadanian; Jeffrey W Cramer; James E Audia; Jeffrey S Nissen; Kelly R Bales; Steven M Paul; Ronald B DeMattos; David M Holtzman
Journal:  J Neurosci       Date:  2003-10-01       Impact factor: 6.167

View more
  49 in total

1.  High-Throughput Screening for Identification of Blood-Brain Barrier Integrity Enhancers: A Drug Repurposing Opportunity to Rectify Vascular Amyloid Toxicity.

Authors:  Hisham Qosa; Loqman A Mohamed; Sweilem B Al Rihani; Yazan S Batarseh; Quoc-Viet Duong; Jeffrey N Keller; Amal Kaddoumi
Journal:  J Alzheimers Dis       Date:  2016-07-06       Impact factor: 4.472

2.  Multi-faceted therapeutic strategy for treatment of Alzheimer's disease by concurrent administration of etodolac and α-tocopherol.

Authors:  Khaled H Elfakhri; Ihab M Abdallah; Andrew D Brannen; Amal Kaddoumi
Journal:  Neurobiol Dis       Date:  2019-01-30       Impact factor: 5.996

3.  Crocus sativus Extract Tightens the Blood-Brain Barrier, Reduces Amyloid β Load and Related Toxicity in 5XFAD Mice.

Authors:  Yazan S Batarseh; Sonali S Bharate; Vikas Kumar; Ajay Kumar; Ram A Vishwakarma; Sandip B Bharate; Amal Kaddoumi
Journal:  ACS Chem Neurosci       Date:  2017-05-15       Impact factor: 4.418

Review 4.  Expression and Processing of Amyloid Precursor Protein in Vascular Endothelium.

Authors:  Livius V d'Uscio; Tongrong He; Zvonimir S Katusic
Journal:  Physiology (Bethesda)       Date:  2017-01

5.  Age-Related Decline in Brain and Hepatic Clearance of Amyloid-Beta is Rectified by the Cholinesterase Inhibitors Donepezil and Rivastigmine in Rats.

Authors:  Loqman A Mohamed; Hisham Qosa; Amal Kaddoumi
Journal:  ACS Chem Neurosci       Date:  2015-03-30       Impact factor: 4.418

Review 6.  Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review.

Authors:  Sophie West; Praveen Bhugra
Journal:  Br J Clin Pharmacol       Date:  2015-06-08       Impact factor: 4.335

Review 7.  In vitro cerebrovascular modeling in the 21st century: current and prospective technologies.

Authors:  Christopher A Palmiotti; Shikha Prasad; Pooja Naik; Kaisar M D Abul; Ravi K Sajja; Anilkumar H Achyuta; Luca Cucullo
Journal:  Pharm Res       Date:  2014-08-07       Impact factor: 4.200

8.  Endothelial LRP1 transports amyloid-β(1-42) across the blood-brain barrier.

Authors:  Steffen E Storck; Sabrina Meister; Julius Nahrath; Julius N Meißner; Nils Schubert; Alessandro Di Spiezio; Sandra Baches; Roosmarijn E Vandenbroucke; Yvonne Bouter; Ingrid Prikulis; Carsten Korth; Sascha Weggen; Axel Heimann; Markus Schwaninger; Thomas A Bayer; Claus U Pietrzik
Journal:  J Clin Invest       Date:  2015-11-30       Impact factor: 14.808

9.  Mixed oligomers and monomeric amyloid-β disrupts endothelial cells integrity and reduces monomeric amyloid-β transport across hCMEC/D3 cell line as an in vitro blood-brain barrier model.

Authors:  Hisham Qosa; Harry LeVine; Jeffrey N Keller; Amal Kaddoumi
Journal:  Biochim Biophys Acta       Date:  2014-07-02

10.  A Role for P-Glycoprotein in Clearance of Alzheimer Amyloid β -Peptide from the Brain.

Authors:  Wei Wang; Angela M Bodles-Brakhop; Steven W Barger
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.